Category: Health

The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children.

The move comes months after the Trump administration touted Leucovorin as a potential therapy for a broader group of patients with symptoms of autism spectrum disorder. The claim sparked skepticism among some medical professionals and researchers, but raised eyebrows among families and led to a surge in prescriptions of the drug in the United States

An FDA official told reporters Monday that “we don’t have enough data to say we could demonstrate efficacy in autism more broadly,” but said the agency was open to interest from companies in studying leucovorin in the autism population.

The drug, also called folinic acid, is a synthetic form of vitamin B9 used to treat the toxic side effects of chemotherapy. Only a handful of small studies suggest that leucovorin may be effective as an off-label treatment for children with autism, and some families have reported that it has helped their nonverbal children develop more language and social skills.

FDA officials, who requested anonymity to discuss the decision, told reporters on Monday that they began a comprehensive review of leucovorin as an autism treatment before narrowing its approval to a smaller population with cerebral folate deficiency, a rare genetic mutation that prevents folate – an important vitamin – from properly reaching the brain.

The condition has similar characteristics to autism, typically occurs in young children under 2 years of age, and can cause severe developmental delays, seizures, lack of muscle control and other serious neurological complications.

The officials said the FDA determined that the use of leucovorin in patients with the condition provided the “high-quality data” to support expanded approval, which will apply to both generic versions of the drug and GSK’s old brand drug Wellcovorin.

“Those were the data where we saw the largest effect sizes,” an FDA official said on the call. “So we narrowed down to this population simply because we felt that was both the strongest scientific case and the largest treatment effect that could be used, and then overcome some of the limitations in the data sources.”

Approval was based on a systematic review of the published literature in the field, including patient case reports, but not on a randomized controlled clinical trial. The same official acknowledged that bias can occur in systematic reviews, but emphasized that the treatment effects were so large that they outweighed these concerns.

The FDA is encouraging existing manufacturers of leucovorin to increase production to meet higher demand for the drug, the officials added. While GSK originally marketed the drug from 1983 to 1997, the company announced in September that it had no plans to relaunch the product and manufacture it itself.

In a press release on Tuesday, Dr. Tracy Beth Hoeg, acting director of the FDA’s Center for Drug Evaluation and Research, said the approval demonstrates the FDA’s commitment to “rapidly identifying effective treatments for extremely rare diseases while maintaining the same standards of evidence for approval.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston.

Brian Snyder | Reuters

Vertex Pharmaceuticals said its experimental drug for a rare kidney disease successfully passed a Phase 3 trial, a key step in the company’s journey to diversify beyond its main cystic fibrosis drugs.

The Boston-based drugmaker said Monday that its immunoglobulin A nephropathy drug, povetacicept, reduced levels of a marker of the autoimmune disease by 52% in a late-stage trial. That exceeded the bar set by analysts for Vertex’s drug to compete with a recently approved drug from Japan’s Otsuka and another in the pipeline from the U.S. biotech company Vera Therapeutics. Shares of Vertex rose more than 9% on Tuesday.

“Vertex’s successful study is an important first step toward entering a new market segment in kidney disease,” said Carter Gould, analyst at Cantor Fitzgerald. Vertex entwickelt zwei Medikamente hinter Povetacicept, und Gould geht davon aus, dass die drei zusammen einen Jahresumsatz von mehr als 10 Milliarden US-Dollar erwirtschaften. That could rival Vertex’s cystic fibrosis franchise, which brought in more than $11 billion in sales last year.

“You don’t have to look really hard to see the connections and say this is a pretty meaningful white space that they could grow into,” Gould said.

Vertex has revolutionized the treatment of cystic fibrosis with a portfolio of drugs for the inherited lung disease, but the company has repeatedly faced questions about whether it could replicate that success in other diseases. The company has expanded into blood disorders in recent years with the approval of its gene-editing drug Casgevy and into acute pain with its drug Journavx. Neither has been a resounding success, forcing Vertex to look for other expansion opportunities.

In 2024, Vertex paid nearly $5 billion to acquire Alpine Immune Sciences and its lead program, povetacicept. The drug could treat a rare autoimmune disease called IgAN, which affects the kidneys’ ability to function properly and sometimes causes patients to need dialysis or even a transplant. Vertex also plans to test the drug for several other kidney diseases.

The company expects to complete its application to the U.S. Food and Drug Administration for povetacicept in IgAN by the end of this month. Approval is possible later this year with the use of a priority review voucher.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

Novo Nordisk has dropped its legal proceedings against the telemedicine provider Him and him for patent infringement after the two companies agreed that Hims would sell Novo’s branded drugs through its platform.

“We have decided to halt the ongoing litigation and of course reserve the right to reopen it if necessary, but I do not expect that to happen,” Novo Nordisk CEO Mike Doustdar told CNBC’s Charlotte Reed on Monday.

Under the agreement, Hims will offer access to injectable and oral semaglutide, sold as Ozempic and Wegovy, at the same price as other telehealth platforms, and Hims will no longer promote compounded GLP-1 drugs on its platform or in its marketing, the companies said in statements Monday.

Shares in Hims rose more than 40% in morning trading, while Copenhagen-listed shares in Novo rose 2.1%. The pan-European blue chip index Stoxx 600 was trading 1% lower while the S&P 500 fell 0.6%.

In February, Novo announced it would sue Hims for “mass illegal compounding” after the latter announced it would sell a copycat version of the Wegovy pill for $49, about $100 less than Novo sells the branded pill through its direct-to-consumer platform NovoCare.

After backlash from Novo and the U.S. Food and Drug Administration, Hims quickly went off the pill. The FDA vowed to take “decisive steps” to restrict the practice by clamping down on pharmacies and referring Hims to the Justice Department for possible violations of federal law.

FDA Commissioner Marty Makary said he was pleased to see that as part of the deal with Novo, Hims would stop promoting unapproved compounded drugs and instead sell FDA-approved products.

“Importantly, they keep them affordable (no price increase) and limit compounded GLP-1s for rare (FDA compliant) cases,” Makary wrote in a post on X.

Hims has benefited enormously from selling copycat versions of the blockbuster weight-loss drug through a loophole in U.S. regulations that allows companies other than the patent holder to sell a drug when it is in short supply.

While semaglutide was in short supply in the drug’s early days, Novo has since resolved supply shortages and ramped up production. However, Hims continued to sell copycat versions of the drugs, arguing that the copies were “personalized” and therefore legal.

Semaglutide is patent protected in the US until 2032.

Last year, Novo and Hims teamed up to offer discounted weight loss vaccinations to the telehealth company’s customers. Novo ended the collaboration just two months later, saying Hims engaged in “misleading” marketing that jeopardized patient safety.

“It’s a very different situation than last time,” Doustdar told CNBC.

“Hims & Hers has agreed that upon receipt of our products, they will no longer advertise or market composite products to the general public,” he said, adding that Hims has now agreed to change its business model to reserve the composite versions “only for the rare occasions when they are needed.”

Stock chart iconStock chart icon

Novo Nordisk ADRs and Hims shares were volatile.

Novo now has more than 600,000 Wegovy pill scripts, Doustdar said.

Doustdar acknowledged that at the time of the Wegovy pill’s launch in January, there were question marks, “a little fueled by our competitor,” that certain food restrictions might limit the pill’s use.

“Well, I have news for you: That was absolutely not the case,” he said. “People are really interested because it’s the most effective pill on the market right now.”

Hims’ existing patients compounding semaglutide “will have the opportunity to switch to FDA-approved medications if their providers deem it clinically appropriate,” Hims said in a statement.

Speaking to CNBC’s Brandon Gomez, Hims CEO Andrew Dudum highlighted the rapidly changing landscape for obesity medications.

“Demand will continue to increase with the new range coming to market and the range really meets needs in terms of affordability, personalization and form factor that did not exist in the past, even just six months ago and 12 months ago,” he said.

Hims is also in discussions with anyone who can bring new therapies to the platform, he added, “be it existing biotech companies or existing large pharma companies.”

Zepbound manufacturer Eli Lilly is expected to launch a competing weight loss pill called orforglipron in the second quarter, pending FDA approval.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

Investors are worried about the fate of several experimental drugs for hard-to-treat diseases after a series of recent rejections by the U.S. Food and Drug Administration (FDA).

According to RTW Investments, the FDA has rejected or advised against the use of at least eight drugs in the past year, including gene therapy for Huntington’s disease UniQurea gene therapy for Hunter syndrome Regenxbio and a medication for a blood disorder Intervertebral disc medicine. The authority initially refused to investigate ModernI got the flu shot before reversing course.

In each case, the FDA took issue with the evidence the companies used to support their applications. In some studies, the drugs were not tested against a placebo. Some companies have not directly measured the drug’s effectiveness, instead relying on other factors such as biomarkers to predict how well the treatment might work.

And in each case, the companies have accused the FDA of reversing its previous guidance. That’s raising concerns among investors that a more unpredictable FDA could jeopardize the future of other treatments for hard-to-treat diseases.

“What investors and key stakeholders want from the FDA is consistency, and it feels like it seems to be lacking at the moment,” said Luca Issi, an analyst at RBC Capital Markets.

In recent years, the FDA appeared willing to accept drugs for rare diseases that showed promise in less rigorous trials than the gold standard randomized, double-blind, placebo-controlled trials. That meant helping to deliver treatments more quickly to patients suffering from conditions where time passes, which can lead to loss of functions such as walking or speaking, or even death. It also sparked controversy among critics who said the policy gave patients false hope.

The FDA’s recent decisions have raised questions among investors about whether the agency’s standards have changed for other drugs in the pipeline. In UniQure’s case, the FDA required the company to conduct a new study directly comparing the treatment with a placebo. UniQure said this contradicts the agency’s previous guidance that the company could apply for approval using trial data that compared UniQure’s treatment with an external database of people with Huntington’s disease.

A former FDA official who spoke to CNBC on condition of anonymity and speaking freely called this the worst kind of regulatory uncertainty because companies say they are told one thing and then experience another.

In a statement, an FDA spokesperson said there is “no regulatory uncertainty,” adding that the agency “makes decisions based on the evidence but makes no representations about the results.” The spokesperson said the FDA “conducts rigorous, independent reviews and does not agree with the approvals.”

Analysts point to several other companies they are watching including Dyne Therapeuticswhich is further developing a drug for Duchenne muscular dystrophy; Taysha Gene Therapieswhich is developing a gene therapy for Rett syndrome; Wave Life Sciencesthat is working on a treatment for liver disease; And Lexeo Therapeuticswhich is developing a gene therapy for Friedreich’s ataxia. Shares of all of these companies are down this year.

A Dyne spokesman said the company has had frequent, positive and collaborative dialogue with a consistent group of reviewers over the past 18 months and is confident in its development strategy and path forward based on the strength of its clinical results, the rigor of its study design and ongoing collaboration with the FDA. Taysha, Wave and Lexeo declined to comment.

One looming decision tracking Stifel analyst Paul Matteis is a drug candidate Denali Therapeutics for Hunter syndrome, a rare disease that causes physical defects such as hearing loss and joint problems, as well as cognitive problems. The company’s application for accelerated approval is based on a non-randomized study and data showing that the drug reduces levels of a biomarker associated with the disease.

For Matteis, the data set is harder to argue with than UniQure’s, and the technology used doesn’t pose much risk.

“So if they don’t approve it, I don’t know,” Matteis said. “I mean, I already think the regulatory standards for rare diseases have changed significantly, but if they didn’t allow Denali, if I were at a company I would almost say to myself, ‘Can we really be confident about doing an open trial?'”

In a statement to CNBC, Denali Therapeutics CEO Ryan Watts said the company continues to have constructive discussions with the FDA and is confident in the strength of the data package presented. The FDA has delayed review of the application for three months and is now expected to make a decision by April 5.

Some investors sense a conflict between the flexibility that FDA leaders like Commissioner Marty Makary are publicly promising and the agency’s recent decisions, said Issi of RBC Capital Markets. “This leads some to discount the likelihood of success for companies whose path to market depends on a degree of flexibility in the data the agency accepts,” said Stifel’s Matteis.

For companies whose data is straightforward, the path seems clear, said Christiana Bardon, managing partner of MPM BioImpact. The question for them is how much the FDA should speed up the process to get drugs to patients for diseases with massive unmet needs as quickly as possible.

A senior FDA official speaking to reporters on condition of anonymity and speaking freely on Thursday said the FDA had not changed its position that biomarkers that could reasonably predict efficacy could and would receive accelerated approval and that non-randomized data could receive full approval. For this officer, the bar is clear.

“If you’re doing treatment for Alzheimer’s or Huntington’s and you give that therapy to someone who’s seriously ill, they’ll immediately and dramatically improve,” the official said. “If you put someone with Alzheimer’s in a nursing home and then leave them, or someone with end-stage HD who suddenly no longer has symptoms of HD, you get full regulatory approval for two or three patients.”

“We only ask for randomized data when a condition is heterogeneous, when the will to believe is strong, when the therapy is invasive or potentially harmful, when the effect size is difficult to detect, and when the likelihood of deluding oneself is high,” the official added.

A few years ago, Grace Guo began to long for places in New York City where hanging out with friends didn’t necessarily have to involve alcohol.

Guo was newly sober and surrounded by friends who also didn’t want to drink. She said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: social wellness clubs that aim to create communities to improve health.

“Honestly, it just feels like going to a spa together and spending an afternoon together. I think for me it just feels a lot better than staying out late at night,” Guo told CNBC.

She is one of a growing number of people who are turning to membership clubs and other places designed to maintain health while also serving as a place to foster connections.

And these spaces are also developing into booming companies. Bathhouse, which opened in Brooklyn, New York in 2019, told CNBC exclusively that it expects run-rate sales of around $120 million by the end of this year. It declined to disclose its other financial information, as did Othership.

Many of these companies are privately owned, but the listed fitness studio chain Life Time also began to focus more on premium wellness a few years ago. While investors initially didn’t like this redistribution of resources, it is now paying off: Life Time shares have more than doubled since October 2023.

Companies old and new are trying to reach consumers like Guo. The 31-year-old said she has noticed an increasing focus on health, well-being and peace in her own social life and those around her, as she seeks so-called third spaces with this focus.

“I’m wondering: Where can I try to join a community, or where can I go to express a particular interest that I have and find like-minded people?” Guo said. “It’s about finding a group of like-minded people, but then also having the space and novelty to try something or pursue something.”

At Othership, Guo said the environment of health-focused socializing between the sauna, the cold bath and choosing a popular time slot in the evening appealed to her.

“It’s really important to have a space where we can go to break ourselves out of our routine and complacency, and I think the most important thing is probably just the fact that it overcomes a lot of the inertia of doing something,” Guo said.

“Loneliness is an epidemic”

Bathhouse pools

Source: Bathhouse

The concept of third spaces is not new. The term was first coined by sociologist Ray Oldenburg in his 1989 book “The Great Good Place” and refers to spaces outside of home, or the first place, and work, the second place, where people come together and build relationships.

This definition included places such as neighborhood cafes, libraries, bars, and more where people of different backgrounds came together in an informal setting with relatively low barriers to entry.

But sometime in recent years, this definition has evolved and the importance of third spaces has increased.

Richard Kyte, a professor at Viterbo University in Wisconsin and author of “Finding Your Third Place,” said he has been teaching courses on third places for nearly two decades but has only noticed the term becoming mainstream in recent years.

That tipping point, Kyte said, also coincided with the pandemic, which put the world into lockdown and virtually eliminated social gatherings for a time but redefined them in the long term.

“During this time, we suddenly started talking more about the cost of loneliness, the cost of social isolation. During the pandemic, we realized that’s not healthy,” Kyte told CNBC. “And at the same time that we realized we needed these places more, we saw so many of them closing. That sparked a new interest.”

It’s a trend also reinforced by an increasingly digital society, he added, as younger generations crave more than just social media connections despite the rise of artificial intelligence and chatbots.

“We’ve made all these huge investments in technology that make it easier and more desirable to be independent,” Kyte said, pointing to AI companies that promote products masquerading as friends. “If we have people turning more to their screens rather than seeking fulfillment through social interaction, all of those people are just going to be taken out of the pool.”

According to Cigna’s 2025 Loneliness in America report, 67% of Gen Zers and 65% of Millennials reported feeling lonely. A 2024 Harvard survey found that 67% of adults experience social and emotional loneliness because they do not belong to a meaningful group.

Harry Taylor initially founded Othership with his wife and friends to create a space that embraced the wellness trend while combating isolation.

“We understand that there is a huge market for meeting other people. Loneliness is an epidemic right now,” Taylor told CNBC. “We realized that just by doing that, people could come together and just be themselves and be vulnerable.”

What is old is new

Third rooms have evolved to encompass specific purposes, justifying the price often associated with them, with some membership clubs earning thousands of dollars per month.

Wellness, in particular, has boomed recently, becoming one of the top gifting categories this past holiday season. Equinox CEO Harvey Spevak told CNBC last month that “health is the new luxury,” with the global wellness market expected to reach nearly $10 trillion by 2030, according to estimates from the Global Wellness Institute.

Bathhouse, which operates 90,000 square foot facilities in New York City, offers a wellness experience based on Europe’s bathhouse heritage. The space features saunas and cold dives, both guided and unguided, starting at $40 for a trial session. The company’s two New York locations serve around 1,000 customers every day.

“It was really obvious that there wasn’t a bathhouse-like concept that was truly aimed at a modern consumer, especially in America,” co-founder Travis Talmadge told CNBC.

Talmadge said he and his co-founder focused on creating a human experience, touching everyone’s body while building a community around the shared activities.

“Our spaces are really large in scale, so the nice thing about it is that everyone feels like a background actor on set where there are just so many people moving around,” Talmadge said. “You can have this really personal time, either alone or with someone else, but then you’re in an environment where a lot of people are doing the same thing.”

Talmadge said the company has seen “excess demand” and is operating at a “very healthy margin” and plans to open seven more locations by 2027.

It is just one of many wellness areas that are becoming increasingly popular.

Othership also draws on a wellness mindset, integrating practices from different cultures to address the “physical, mental, emotional and spiritual.” The company has locations in New York and Canada and plans further growth.

At Othership, members can choose between three options: a free-flow session, which allows members to use the space as they wish; Courses that alternate between saunas and cold dives with group-led activities; and social gatherings, imitating clubs without alcohol in order to be present.

Co-founder Taylor said that through Othership, he has seen customers create new friend groups, propose to their partners in the sauna, and find belonging with others while strengthening their own health.

Creating alcohol-free spaces was one of the Othership founders’ goals when developing the vision. Othership now hosts comedians, live musicians and more in its saunas, replicating similar spaces found in big cities that are often associated with alcohol.

“There is so much social media that gives us the false impression of social engagement and interaction, but so many of us have found ourselves doomscrolling to almost do the opposite,” Taylor said. “As we all need social saturation as humans, a gap is created. Therefore, it is coming together and genuinely interacting with each other that truly creates a deep sense of belonging.”

Building community

Glo30 Skin Care Studio.

Courtesy: Arleen Lamba

Wellness communities can also emerge in other ways. Glo30, a membership studio founded 13 years ago with locations across the country, offers members personalized skin care treatments every 30 days and creates a coordinated schedule with other members to foster community.

“Building community is not just about achieving results [feeling] good, but also being able to have common experiences and share their feelings,” Arleen Lamba, founder and CEO of Glo30, told CNBC.

While urban cities like New York and Los Angeles are seeing a boom in wellness clubs, Lamba says their more than 100 locations represent the in-between, in places like Texas, Arizona, North Carolina and elsewhere.

Each Glo30 appointment is scheduled on the hour at each location to create more opportunities for social connection, Lamba said.

“When people come into the studio, they leave the studio, and we see that they would recognize each other and actually make new friends,” she said, adding that the company has seen more and more social groups forming in the treatment rooms, especially after the pandemic.

Lamba said she has observed that the desire for social connection has increased with the advent of social media, but that creating community can often happen in unconventional places like Glo30. At the same time, this social interaction is not as “overwhelming” as other venues such as parties or large group events, allowing for an intimate social gathering, she said.

Lamba said Glo30’s number of franchise units in development has increased by 67.5% over the past two years as demand for its services has increased.

But the boom in third spaces also goes beyond wellness. Exclusive restaurant memberships, gyms, creative spaces, social clubs and more are becoming increasingly popular as consumers look for ways to build community outside of their homes and offices.

At Glo30, Lamba said she has seen every customer base at the company’s locations, from families to girl groups to couples.

“The third room is interesting because it creates a real connection,” she said. “We witness someone’s life – their highs, their lows, their mids – and we are the constant, and that’s what the third room is all about to me: No matter what kind of day you’ve had out there, good, bad or mediocre, this room is yours. And when you come into this room, people will know you, see you, appreciate you and be glad you’re there.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

The Food and Drug Administration logo is seen before a press conference at the Health and Human Services headquarters on April 22, 2025 in Washington, DC.

Nathan Posner | Anadolu | Getty Images

A key U.S. Food and Drug Administration official who oversees vaccines and biotechnology treatments will resign from the agency after several decisions that raised concerns in the industry.

Vinay Prasad, director of the Center for Biologics Evaluation and Research, will leave the FDA at the end of April, an agency spokesman confirmed Friday. It is his second resignation from the position: He briefly left the post in July after backlash over his regulatory decisions, and returned just two weeks later in August.

In a post on Makary, Prasad said “achieved tremendous things” during his tenure at the agency.

Prasad’s decision to resign comes after criticism of the FDA grew from the biotech and pharmaceutical industries, as well as from former health officials. According to RTW Investments, the agency rejected or discouraged approval applications for at least eight drugs last year after delving into the data the companies used to support their applications. The FDA also refused to review Moderna’s flu shot before changing course.

All of these companies accused the FDA of reversing previous guidance on the evidence they could use to support their applications, sparking industry criticism that an unreliable regulatory process could hamper the development of drugs for hard-to-treat diseases.

A former FDA official, who spoke to CNBC on condition of anonymity to speak freely on the topic, called the retractions the worst kind of regulatory uncertainty because companies say they are told one thing and then experience another.

In a statement earlier Friday, an FDA spokesperson said there is “no regulatory uncertainty,” adding that the agency “makes decisions based on the evidence but makes no representations about the results.” The spokesperson said the FDA “conducts rigorous, independent reviews and does not agree with the approvals.”

The latest controversy came after the FDA advised against it UniQure disqualified from applying for accelerated approval of its experimental treatment for Huntington’s disease.

The agency, which made staff cuts and reorganization under Health and Human Services Secretary Robert F. Kennedy Jr., has faced broader backlash for its approval process for drugs and vaccines. Critics fear the agency could hinder the development of new treatments and endanger patient safety.

The Wall Street Journal previously reported Prasad’s departure.

Thomas Fuller | SOPA images | Light rocket | Getty Images

UniQure needs to conduct another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said in a call with reporters on Thursday.

The official, who spoke on condition of anonymity before discussing confidential information, confirmed that the agency had asked the company to conduct a placebo-controlled trial of its treatment, which is administered directly into the brain. UniQure has said this type of study would not be ethical because it would require hours of general anesthesia, a characterization the official disputed.

“So what’s really going on? UniQure is the latest company to develop a failed therapy for HD patients,” the official said. “They probably recognize or understand on a deeper level that their study failed years ago, and instead of doing the right thing and conducting the right clinical trial, UniQure is running a distorted or manipulated comparison in the mind of the FDA.”

The comments mark the latest development in a messy public dispute between UniQure and the FDA and as the agency comes under fire for a series of recent rejections of drug applications, including some in which companies have accused it of deviating from previous guidance. FDA Commissioner Marty Makary appeared to criticize UniQure’s gene therapy for Huntington’s disease in an interview with CNBC’s Becky Quick last week. Makary did not name UniQure but described his treatment.

UniQure then accused the FDA of changing its stance that the company’s clinical trial data would be sufficient to seek approval. The UniQure study used an external database to measure how patients with Huntington’s disease might worsen without treatment, a so-called external control. UniQure has said that it would not be feasible to conduct a truly randomized, double-blind, placebo-controlled trial, which is considered the gold standard, because it would be ethical to subject people to hours of sham brain surgery.

The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we’ll have to see the data when we get it.'”

UniQure did not immediately comment.

The company’s stock rose more than 10% on Thursday and has fallen 58% this year since Thursday afternoon.

The secretary of the US Health and Human Services (HHS), Robert F. Kennedy Jr., speaks when he participates at a press conference with centers for Medicare and Medicaid services Mehmet OZ to discuss the health insurance of health insurance at the Department of Health and Human Services in Washington, DC on June 23, 2025.

Kevin Mohatt | Reuters

A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.

Robert F. Kennedy Jr., Secretary for Health and Human Services, recently disappointed an important state vaccine panel and said that it was necessary to remove what he described as “persistent conflicts of interest” in the committee.

New research results of the USC Schaeffer Center for Health Policy & Economics seem to question this argument. Conflicts in these centers for the control and prevention of diseases have been on “historical lows” for years before Kennedy repeated it with new members, some of whom are well -known vaccine critics, the researchers found.

The study published on Monday, published in the Medical Journal Jama, also showed that the type of conflict, which was considered “most worrying” – was practically eliminated by the members of the members of the Choir Committee on Immunization Practices or ACIP.

The interest conflicts were also low at a separate advisory committee of the Food and Drug Administration as vaccines and related biological products.

Both groups are crucial for the design of the US vaccine policy: While the agency's FDA committee advises whether shots should be approved, the CDC committee determines who is entitled to JABS and whether the insurers should cover them. The panels usually consist of top experts for infectious diseases, pediatrics, immunology and public health.

Kennedy has long claimed that the consultants of these panels have close relationships with the pharmaceutical industry. At his first hearing to confirm the Senate in January, Kennedy claimed that 97% of the members of the CDC committee had conflicts of interest.

“Before it was confirmed, I saw this 97% number and thought that there were some serious things. But after I had looked at the vaccine data myself, I could certainly see nothing of this size,” said the leading author of the study in an interview.

“I think it will be the public and that [Trump] Administration that problems that we thought were quite serious or were serious in the past were no longer, ”she added.

As Kennedy, a prominent vaccine skeptic himself, the health authorities of the federal government is overhauled and pursues efforts that change the immunization policy and undermout the vaccine in the United States

The USC researchers analyzed financial interests among experts for the two vaccine boards between 2000 and 2024.

The conflicts of interest on the panels, which meet several times a year to check vaccines several times a year: For every product that is discussed, the members must say whether they have a tie to the vaccine manufacturer or a competitor and disclose the nature of the relationship. People on the committee with conflicts either receive a waiver of participation if they are regarded as essential specialist knowledge, while those with excessive conflicts are withdrawn.

According to the paper, an average of 6.2% of the ACIP members and 1.9% of the VRBPAC members have reported a financial conflict of interest at a certain session since 2016. During this period, less than 1% of the conflicts reported in both panels were bound to the personal income of vaccines, including advice fees, stocks, license fees or property.

The reported conflicts between ACIP members fell to 5% by 2024 and have remained under 4% at VRBPAC members since 2010, including 10 years in which no conflicts were reported at all.

The interest rate conflicts were significantly higher in the early 2000s and achieved around 43% for ACIP and 27% for VRBPAC at ACIP in 2007, as the researchers found.

The study states that the decline over the years could be due to political changes in 2007, which are due to conflicts of interest in the FDA committee, as well as “greater awareness and review” of the conflicts in the agency's decision-making. It is not clear when exactly the CDC committee did the same.

During the entire study period, the most frequently reported conflicts of interest was the research support, which is generally less important than financial bonds associated with personal income. Kanter said this was a reflection of the fields of the panel members who are relevant for the evaluation of security, effectiveness and applicability of shots.

“The dominant conflicts were to grant support for research. In a way that makes sense because we want to in these committees?

“These conflicts are not about personal profit, but about specialist measures.”

While some of the rates seem to be higher in ACIP members than with people of the VRBPAC committee, Kanter did not say comparable because the CDC provides “far less detailed” data on conflicts of interest. She added that the FDA committee typically checked one product during a session, while the CDC committee rates several.

Kanter said it was important to examine conflicts of interest and the influence of the pharmaceutical industry in many aspects of health regulation.

However, she added that “if we want to concentrate on conflicts of interest, there may be other areas in which prevalence is a bigger problem than what we have seen here with these vaccine boards.”

Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.

Buffett Bounce from Unitedhealth stops in the healthcare system for the time being

Warren Buffett was exactly what the doctor had stabilized Unitedhealth Group Shares.

The 13F registration from Berkshire Hathaway, which unveiled a new participation of more than 5 million shares, contributed to lifting the stock over $ 300-away from the 52-week low of less than $ 235, which it reached at the beginning of this month.

This is Berkshire's first excursion to the complicated area of managed care. The Appaloosa Fund from David Tepper also provided a vote of trust in the shares of the competitive health giant and increased its share to 2.5 million shares.

For both it is a bet on recovery, but analysts say that waiting could take well over a year. When evaluating the purchases, the Baird analyst Michael Ha Warren Buffett's own words called “complicated, uncertain investments”, which belong in the “too hard stack”.

In a reference to the customers, HA wrote that the problems of Unitedhealth about pricing in his Medicare advantage plans for real structural problems with his optum health doctor unit, which are not so easy, extend. HA added that “the short -term execution risk is high and that we see the potential that the situation deteriorates in the next 12 to 18 months before it improves.”

For the time being, Unitedhealth shares have been exceeded for the first time on their sliding 50-day average since the company in April.

Feel free to send tips, suggestions, stories ideas and data to Bertha at Bertha.coombs@nbcuni.com.

Latest in the healthcare system Tech: Epic Touts New AI tools in the annual user group meeting

Epics campus in Verona, Wisconsin

With kind permission: epic

This is Ashley, who reports live from Verona, Wisconsin.

It is this season again! I take part in the annual user group assembly of EPIC, in which thousands of health care managers flock to the company's 1,670 hectare headquarters in order to learn more about the latest products and functions of the company.

EPIC is a company for health software known for its electronic health records or honorary software. An honor is a digital version of the medical record of a patient who is cultivated by doctors and nurses over time. Epic is the dominant honorary provider in the United States, and according to the company, its technology is used in 3,300 hospitals and 73,000 clinics and 325 million patients all over the world.

The artificial intelligence was near and in the center in the UGM this year, similar to how it was last year. During a three-hour management address on Tuesday morning, epic managers shared updates about the approximately 200 new AI characteristics they developed for patients, clinicians and payers. Pay attention to an additional coverage of CNBC, which explains some of these upcoming functions in more detail.

Epic confirmed that it developed its own AI-driven clinical documentation instrument that was one of the most expected announcements of this year's event. These tools, which are often referred to as AI fonts, can create clinical notes in real time when doctors record their visits to patients mutually.

A highly competitive AI writing market has been looking for solutions as managers in the healthcare system to reduce employees of employees and discouraging administrative workload. Some AI writing startups such as moving and ambience Healthcare have collected hundreds of million dollars from investors, and there was a lot of speculation about whether Epic finally joined the fight.

The company said it was working with Microsoft on this function and will be available for limited use at the beginning of next year.

“Ai is here, it accelerates, you cannot wish you, you have to keep pace with it,” said the President of Epic, Sumit Rana, during the address.

The presentations took place in the underground auditorium with the underground auditorium of Epic called Deep Space, which is only one of the many unique facilities on the campus. The Epic office buildings are discussed, many inspired by science fiction and stories such as “The Wizard of Oz”, the Harry Potter series and “Alice in Wonderland”.

UGM meetings are also discussed, and epic managers are famous for the stage in costumes. This year's topic was “Sci-Fi”, and the 82-year-old founder and CEO of Epic, Judy Faulkner, wore a purple wig, light green shoes and a metallic vest that was inspired by the fictional figure Buzz Lightyear.

CNBC had the opportunity to put together in a rare interview with Faulkner at the beginning of this summer, in which she thought about her 46 years at the rudder of the company. During her presentation on Tuesday, Faulkner discussed the KI initiatives and the Roadmap of Epic.

“We combine human intelligence and curiosity with the investigative skills of Gen AI,” she said.

Many of the new features played on Tuesday on Tuesday are still several months or over a year. But it is clear that Epic relies on AI, and they have not allowed the UGM participants to forget it this year.

Read more about CNBC's interview with faulkner.

Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.